Assessment | Domain | Baseline evaluation (T0) | 3-month evaluation (T1) | 6-month symptoms (T2) | 12-month evaluation (T3) | 24-month evaluation (T4) |
---|---|---|---|---|---|---|
Interview • Demographic registry | General condition | √ | √ | √ | √ | √ |
• Past disease history | √ | √ | √ | √ | √ | |
• Vascular risk factors (e.g., smoking, alcohol consumption) | √ | √ | √ | √ | √ | |
• Family history | √ | - | - | - | - | |
Clinical assessment • Blood pressure, instant blood sugar | Health condition | √ | √ | √ | √ | √ |
• National Institutes of Health Stroke Scale, Modified Rankin Scale | √ | √ | √ | √ | √ | |
• Physical and neurological examination | √ | √ | - | √ | √ | |
Primary outcome measure | Corneal function | √ | √ | - | √ | √ |
• OSDI | Tear secretion | √ | √ | - | √ | √ |
• Schirmer test | √ | √ | - | √ | √ | |
• Non-invasive tear film breakup time | √ | √ | - | √ | √ | |
• Thickness of lipid layer of lacrimal film | √ | √ | - | √ | √ | |
• PBR | √ | √ | - | √ | √ | |
• Corneal sensation | Corneal sensation | √ | √ | - | √ | √ |
• BSCVA | Vision | √ | √ | - | √ | √ |
• ASOCT | Anterior segment | √ | √ | - | √ | √ |
• Meibomian gland and lipid layer | √ | √ | - | √ | √ |